TIDMFARN
Faron Pharmaceuticals Oy
19 April 2023
Faron Pharmaceuticals Oy
("Faron or the Company")
Bexmarilimab for Hematological Malignancies KOL Event
Press Release, April 19, 2023
TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM:
FARN, First North: FARON), a clinical-stage biopharmaceutical
company focused on tackling cancers via novel immunotherap ies,
today announces plans to host a virtual KOL event via webcast on
Tuesday, April 25 at 11.00 EST/16.00 BST/18.00 EEST with Dr. Naval
Daver, MD, Associate Professor of Leukemia at The University of
Texas MD Anderson Cancer Center; Dr. Mika Kontro, MD, PhD,
Associate Professor at the University of Helsinki and Faron
management.
As part of the event, Dr. Daver will discuss the unmet medical
need in acute myeloid leukemia (AML) and myelodysplastic syndrome
(MDS). Dr. Kontro will provide an update on the most recent Phase
I/II BEXMAB data in AML and MDS patients.
The agenda is as follows:
-- Opening remarks and introductions - Dr. Markku Jalkanen, PhD, CEO
-- Unmet medical need in r/r AML and MDS - Dr. Naval Daver, MD, Scientific Advisor for Faron
-- BEXMAB clinical data in combination with standard of care - Dr. Mika Kontro, MD, PhD
-- Next steps planned for the study - Dr. Marie-Louise Fjällskog, MD, PhD, CMO
-- Q&A session
-- Closing remarks
Faron reported this week updated additional positive data from
its ongoing Phase I/II BEXMAB study, investigating bexmarilimab,
the Company's wholly owned immunotherapy asset, in combination with
standard of care (SoC) in relapsed/refractory acute myeloid
leukemia (AML) and myelodysplastic syndromes (MDS). The latest
update included two objective responses (ORR) and two stable
disease (SD) patients observed, with one having > 50% reduction
of blast cells, in the second doublet cohort. Of three patients
with ORR in the first doublet cohort, two remain on the study after
10 and 9 months, respectively, and the third has undergone a
potentially curative transplantation.
During the event, Dr. Marie-Louise Fjällskog, Faron's Chief
Medical Officer, will discuss next steps planned for the BEXMAB
program. There will be an opportunity to ask questions during the
webcast.
"I am delighted to be hosting this KOL Day with Dr. Daver and
Dr. Kontro," said Dr. Markku Jalkanen, Faron's CEO. "They will
provide important insights into the immunotherapy approaches
currently available to patients with hematological malignancies and
the work Faron is doing to potentially bring the promise of
immunotherapy to a broader patient group."
To register for the webcast:
https://faron.videosync.fi/kol-call-04-2023/register or contact the
IR team for more information at investor.relations@faron.com .
For more information please contact:
Media Contact
Faron Pharmaceuticals
Jennifer C. Smith-Parker
Head of Communications
Jennifer.Smith-Parker@faron.com
Investor Contact
Faron Pharmaceuticals
Julia Balanova
VP, Investor Relations
julia.balanova@faron.com
investor.relations@faron.com
Phone: +1 (917) 306-6096
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
Consilium Strategic Communications
David Daley, Lindsey Neville
faron@consilium-comms.com
Phone: +44 (0)20 3709 5700
About Bexmarilimab
Bexmarilimab is Faron's wholly owned, investigational
immunotherapy with the potential to provide immune stimulation for
treatment-resistant cancers through targeting myeloid cell
function. A novel anti-CLEVER-1 humanized antibody, bexmarilimab
targets CLEVER-1 positive (Common Lymphatic Endothelial and
Vascular Endothelial Receptor 1) tumor-associated macrophages
(TAMs) in the tumor microenvironment, converting highly
immunosuppressive M2 macrophages to immune-stimulating M1
macrophages. As an immuno-oncology therapy, bexmarilimab has
therapeutic potential in combination with other standard treatments
including immune checkpoint molecules in both solid tumors and
hematologic malignancies.
About BEXMAB
The BEXMAB study is a first-in-human, open-label Phase I/II
clinical trial investigating bexmarilimab in combination with
standard of care (SoC) in the aggressive hematological malignancies
of acute myeloid leukemia (AML) and myelodysplatic syndrome (MDS).
The primary objective is to determine the safety and tolerability
of bexmarilimab in combination with SoC (azacytidine) treatment and
to identify the recommended Phase II dose. Directly targeting
CLEVER-1 could limit the replication capacity of cancer cells,
increase antigen presentation, ignite an immune response, and allow
current treatments to be more effective. CLEVER-1 is highly
expressed in both AML and MDS and associated with therapy
resistance, limited T cell activation and poor outcomes.
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON),
together with its subsidiaries, is a clinical stage
biopharmaceutical group focused on building the future of
immunotherapy by harnessing the power of the immune system to
tackle cancer. Bexmarilimab , a novel anti-CLEVER-1 humanized
antibody, is its investigational immunotherapy with the potential
to remove immunosuppression of cancers through targeting myeloid
cell function. Bexmarilimab is being investigated in Phase I/II
clinical trials as a potential therapy for patients with
hematological and solid cancers in combination with other standard
treatments including immune checkpoint molecules. Faron is
headquartered in Turku, Finland. Further information is available
at www.faron.com .
Forward-Looking Statements
Certain statements in this announcement are, or may be deemed to
be, forward-looking statements. Forward looking statements are
identified by their use of terms and phrases such as "believe",
"could", "should", "expect", "hope", "seek", "envisage",
"estimate", "intend", "may", "plan", "potentially", "will" or the
negative of those, variations or comparable expressions, including
references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Directors' current
expectations and assumptions regarding the Company's future growth,
results of operations, performance, future capital and other
expenditures (including the amount, nature and sources of funding
thereof), competitive advantages, business prospects and
opportunities. Such forward-looking statements reflect the
Directors' current beliefs and assumptions and are based on
information currently available to the Directors.
A number of factors could cause actual results to differ
materially from the results and expectations discussed in the
forward-looking statements, many of which are beyond the control of
the Company. In addition, other factors which could cause actual
results to differ materially include the ability of the Company to
successfully license its programs within the anticipated timeframe
or at all, risks associated with vulnerability to general economic
and business conditions, competition, environmental and other
regulatory changes, actions by governmental authorities, the
availability of capital markets or other sources of funding,
reliance on key personnel, uninsured and underinsured losses and
other factors. Although any forward-looking statements contained in
this announcement are based upon what the Directors believe to be
reasonable assumptions, the Company cannot assure investors that
actual results will be consistent with such forward-looking
statements. Accordingly, readers are cautioned not to place undue
reliance on forward-looking statements. Subject to any continuing
obligations under applicable law or any relevant AIM Rule
requirements, in providing this information the Company does not
undertake any obligation to publicly update or revise any of the
forward-looking statements or to advise of any change in events,
conditions or circumstances on which any such statement is
based.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGPUWCCUPWPUR
(END) Dow Jones Newswires
April 19, 2023 02:00 ET (06:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024